Interestingly, in the T-ALL mouse model, this kinase pathway was also activated in the rare leukemia-initiating cell population, suggesting that inhibition of MAP2K7 could potentially eradicate leukemia-initiating cells responsible for chemoresistance and relapse. Here, MAP2K7 is linked to acute lymphoblastic leukemia.